1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Padagis Starts Life Post-Perrigo With Eucrisa Challenge

Anacor Sues Former Perrigo Rx Unit After Crisaborole Paragraph IV Filing

 
• By Dave Wallace

Padagis, the former Perrigo Rx business that was acquired by Altaris in July, has seen litigation initiated by Eucrisa originator Anacor over its Paragraph IV ANDA filing for crisaborole 2% ointment.

Start Sign Road
Padagis has made a new start after being acquired by Altaris in July • Source: Alamy

Padagis, the former Perrigo ‘Rx’ prescription pharmaceuticals business that was acquired by Altaris Capital Partners in July, has been sued by Anacor over its Paragraph IV abbreviated new drug application for a US generic rival to Eucrisa (crisaborole) 2% ointment.

Litigation over Eucrisa – which is indicated for mild-to-moderate eczema (atopic dermatitis) in adults and children over three months of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By Dave Wallace

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By Dave Wallace

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By Dave Wallace

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

More from Business

Krka Passes €1bn Threshold In Just Six Months

 
• By Dean Rudge

Krka has reported its strongest-ever half-year results, surpassing €1bn in sales and growing EBITDA by 8%. Solid performance across most regions, particularly Eastern and Central Europe, supported stable margins and a positive full-year outlook.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By Dave Wallace

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.